Industry News

InfuSystem Holdings, Inc., a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today announced that its chief financial officer, Jonathan P. Foster, has resigned effective August 11, 2016 to pursue a similar role with another public company. Effective August 11, 2016, the Company will appoint Christopher Downs, CTP, FP&A, its current vice president&..."/>
InfuSystem Holdings, Inc. Announces Resignation Of Chief Financial Officer And Replacements
LifePoint Health, Inc. today announced results for the second quarter and six months ended June 30, 2016.. For the second quarter ended June 30, 2016, consolidated revenues were $1,592.4 million, up 25.3% from $1,270.4 million for the same period last year, primarily as a result of our recent acquisitions in Flemingsburg, Kentucky, Jeffersonville, Indiana, Watertown, Wisconsin, Hickory, North Carolina, Sanford, North Carolina, Columbus, Georgia and Columbia,..."/>
LifePoint Health Reports Second Quarter 2016 Results
Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced the upsizing and pricing of its previously announced underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $6.00 per share. In addition, Chembio has granted the underwriters a 30- day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any."/>
Chembio Diagnostics, Inc. Announces Upsizing And Pricing Of Public Offering Of Common Stock
Ultragenyx Pharmaceutical reported on Thursday the completion of adult patient enrollment under the Phase 3 study of KRN23 for the treatment of adults with X-linked hypophosphatemia, with expected clinical data in 2017.. This Phase 3 study is a randomised, double-blind, placebo-controlled clinical study designed to assess the efficacy and safety of monthly KRN23 in 134 adult XLH patients in the US, EU, Canada, Japan, and Korea who are experiencing..."/>
Ultragenyx concludes X-Linked Hypophosphatemia adult patient admission in Phase 3 Study of KRN23
Pfizer for undisclosed financial terms. According to the partnership, the oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. The companies added that WO-12 is a preclinical..."/>
Pfizer partners with Western Oncolytics for oncolytic virus development trials
Teleflex Incorporated on Thursday announced the declaration by its board of directors of a quarterly cash dividend of USD0.34 per share of common stock. The dividend pay out will be made on 15 September 2016 to shareholders of record at the close of business on 15 August 2016.. A provider of medical technologies designed to improve the health and quality of people's lives, Teleflex offers solutions in the fields of vascular and interventional access, surgical, anaesthesia,..."/>
Teleflex’s board declares USD0.34 quarterly dividend
Oculus Innovative Sciences announced on Thursday gross profit of USD1.9m, or 50% of revenue, for the first quarter of fiscal year 2017 ended 30 June 2016.. This is almost flat when compared with a gross profit of USD1.9m, or 51% of revenue when compared to the corresponding period in the prior year. Total revenues of USD3.8m were collected for the first quarter, an increase over total revenues of USD3.7m for the same period in 2015.."/>
Oculus Innovative Sciences discloses Q1 fiiscal 2017 gross profit of USD1.9m
Agile Therapeutics reported on Thursday the election of Seth H. Z. Fischer to its board of directors' compensation and nominating& corporate governance committees with immediate effect. Currently, Fischer is the chief executive officer and a director of Vivus, Inc, a member of the board of directors of BioSig Technologies, Inc as well as an advisor to MedHab. Fischer previously served in positions of increasing responsibility with Johnson& Johnson from..."/>
Agile Therapeutics elects Seth H. Z. Fischer to its board
Spring Bank Pharmaceuticals revealed on Thursday the addition of Todd C. Brady, PhD, MD, AB to its board of directors with immediate effect. Currently, Dr Brady works as the chief executive officer& president of Aldeyra Therapeutics since 2012 as well as a member of its board of directors since 2005.. Dr Brady has recently served as entrepreneur in Residence at Domain Associates, as well as was part of Xanthus Life SciencesInc and Phenome Sciences earlier..."/>
Spring Bank Pharmaceuticals elects Dr Todd C. Brady to board
Reliance Infrastructure Ltd for an enterprise value of Rs.8, 000 crore,..."/>
Deals Buzz: Brookfield front runner to buy out Anil Ambani's road assets [Mint, New Delhi]
Diplomat Pharmacy, Inc. is recognizing World Hepatitis Day with a campaign to raise awareness of the disease and honor patients who have felt its effects. World Hepatitis Day occurs annually July 28.."/>
Diplomat to Recognize Patients with World Hepatitis Day Campaign - Diplomat
Centene's proposed expansion defended their request for public assistance Thursday, arguing the project meets the area's long-term development goals by adding residents and retail near public transit and drawing thousands of high-paying jobs to the region's central corridor. It's hardly in dispute that, if fully developed, the westward expansion of the Medicaid managed-care company's campus would transform Clayton. As many as three high-rise..."/>
Clayco touts benefits of Centene project, argues incentives are in line with existing building [St. Louis Post-Dispatch]
Pfizer Inc. 100 percent ownership of its business in the Kingdom to, among other things, import, export and trade in products, permitting a supply of quality innovative and essential medicines directly to the Saudi market. The new license is effective immediately. Majid Al-Qassabi, minister of commerce and investment, and chairman of SAGIA's board of directors, said: "As one of the..."/>
SAGIA grants Pfizer 100% ownership of KSA business [Arab News, Jeddah, Saudi Arabia]
Cipla Ltd, India's fifth largest drug maker, on Thursday announced that it has acquired a portfolio of three products from Teva Pharmaceutical Industries Ltd in the US, which are being divested by the Israel-based company as a precondition to its $40.5 billion acquisition of Allergan Plc's generic business. The spokesperson for Cipla confirmed the purchase without disclosing financial and product details. According to the US Federal Trade Commission,..."/>
Cipla, Aurobindo Pharma acquire products divested by Teva in US [Mint, New Delhi]
Boston Scientific Corp. is ramping up sales of medical devices made in Minnesota and elsewhere, but a decision to halt sales and write down the inventory of a next-generation device to prevent strokes is keeping company earnings in check. The med-tech company, which employs about 7,300 people in the Twin Cities, raised its financial outlook for the year on Thursday and reported companywide revenue that exceeded analyst expectations. That stemmed partly from Boston..."/>
Boston Scientific swings to loss on one-time items, but outlook upbeat [Star Tribune (Minneapolis)]
Cigna may not move forward as quickly as Anthem officials hoped. The DOJ filed a lawsuit July 21 to block the proposed $54 billion acquisition, stating the deal could have a negative impact on consumers."/>
Feds Say No Reason To Rush Anthem-Cigna Case To Trial [The Hartford Courant]
Avita Medical Ltd.,, a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced its financial results and business update for the fourth quarter of fiscal 2016 which concluded on June 30, 2016.. Total cash inflows of $1.1 m for the quarter and $4.4 m for the year Cash receipts from BARDA totalled $2.1 m for the year Net operating cash outflows of $2.6 m for the..."/>
Avita Medical Announces Financial Results for Fourth Quarter Fiscal 2016
MIDDLEFIELD BANC AND LIBERTY BANK TO MERGE IN USD 40.8 M DEAL Ohio-based bank holding company Middlefield Banc Corp. has entered into an agreement and plan of reorganisation with Ohio-based Liberty Bank, N.A., the company said. Middlefield is the holding company for The Middlefield Banking Co. Under the terms of the agreement, Liberty shareholders will have the option to receive either..."/>
M and A Navigator: Deal pipeline –29 July
Derma Sciences, Inc. has agreed to acquire US-based biotechnology company BioD, LLC for an immediate transaction value of USD 21.3 m and a potential total transaction value of an estimated USD 77.8 m, the company said. This includes an upfront payment of cash and common stock of USD 21.3 m, as well as potential product regulatory milestone payments in aggregate estimated to be up to USD 30.0 m and earn outs based on incremental net..."/>
Derma Sciences to Acquire US Biotechnology Firm BioD for up to USD 77.8m

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials953 Articles
Information Technology898 Articles
Consumer Discretionary751 Articles
Health Care595 Articles
Industrials595 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.